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Abstract: We compared the impact of a high versus low energy intake first meal on glucose and
insulin responses during prolonged sitting in individuals with prediabetes. Thirteen adults with
overweight/obesity and prediabetes (mean ± SD age: 60 ± 6 years, BMI: 33 ± 4 kg/m2; 2 h OGTT:
8.9 ± 1.1 mmol/L) completed two randomised trials: 10 h uninterrupted sitting, incorporating three
meals with matching macronutrient compositions but different energy distributions: High-Energy
Breakfast (HE-BF; breakfast: 50%, lunch: 30%, dinner: 20% energy intake), Low-Energy Breakfast
(LE-BF: 20%/30%/50% energy intake). Venous blood was sampled from 08:00–18:00 h for
determination of plasma glucose and insulin concentrations, with 24 h continuous glucose monitoring
(CGM). Total glucose area under the curve (AUC; +5.7 mmol/L/h, p = 0.019) and mean plasma
glucose concentrations (+0.5 mmol/L, p = 0.014) were greater after HE-BF compared to LE-BF. In the
HE-BF condition, compared to LE-BF, there was a greater incremental area under the curve (iAUC)
for plasma glucose post-breakfast (+44 ± 59%, p = 0.007), but lower iAUC post-lunch (−55 ± 36%,
p < 0.001). Total insulin AUC was greater (+480 mIU/mL/h, p < 0.01) after HE-BF compared to
LE-BF. Twenty-four-hour (24 h) CGM revealed no differences in mean glucose and total AUC between
conditions. Compared to a low-energy first meal, a high-energy first meal elicited exaggerated plasma
insulin and glucose responses until lunch but had little effect on 24 h glycaemia. During periods of
prolonged sitting, adults with prediabetes may have more beneficial postprandial insulin responses
to a low-energy first meal.
Keywords: glyacemic control; breakfast; obesity; sedentary behavior; insulin; energy distribution
1. Introduction
The continued rise in the prevalence of obesity and the rate of diagnosis of individuals with
type 2 diabetes (T2D) imposes a substantial burden on healthcare systems. As such, adults with
prediabetes, who spend a large proportion of their day in a state of postprandial hyperglycaemia [1],
have become a key target group for preventive lifestyle interventions in an effort to prevent T2D [2]
and associated cardiovascular complications [3]. The magnitude of postprandial glucose excursions
across the day and night have become a major clinical focus in treatment strategies for individuals
with prediabetes [4]. Understanding the extent to which behavioural factors, such as meal size and
prolonged periods of inactivity, influence the postprandial state is essential for future management of
adults with prediabetes.
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In recent decades, substantial changes in the modern environment have been evident, specifically
increases in the time spent in sedentary behaviour (sitting). Sedentary behaviour is associated with
increased risk of T2D even after accounting for habitual physical activity levels [5,6]. Both observational
and experimental studies demonstrate that prolonged sitting is detrimental to postprandial glucose
levels [7], where the greatest exaggeration in hyperglycaemia with prolonged sitting occurs in the
period after the first meal [8,9]. Therefore, optimising the daily distribution of energy may be a practical
strategy for modifying postprandial hyperglycaemic responses to meals.
Several studies have shown reductions in body mass, waist circumference and daily
hyperglycaemia following 7 days to 12 weeks of consuming a large breakfast (50% energy intake (EI))
meal compared to an energy-matched large dinner meal during energy restriction, in both individuals
with metabolic syndrome [10] and T2D [11,12]. Despite the reduction in daily hyperglycaemia,
exaggerated postprandial hyperglycaemia at breakfast was observed when a large breakfast was
consumed compared to a smaller, typical breakfast-sized meal (~20% EI). However, a shortcoming
when interpreting the results from these interventions is that they have used a protocol whereby the
energy content of the meal and the macronutrient composition have been simultaneously altered.
Specifically, a higher carbohydrate (CHO) meal in the morning (45% CHO, 25% protein), rather than
at the end of the day, has been shown to improve total daily area under the curve (AUC) compared
to a smaller breakfast first meal higher in protein (10% CHO, 65% protein) [10,12]. Subsequently,
the large morning meal was balanced by a smaller, high-protein meal in the evening. As insulin
sensitivity is greatest upon waking compared to the end of the day [13], the larger CHO meal consumed
at the beginning of the day is ingested when insulin sensitivity (i.e., beta-cell function) is highest.
Furthermore, the composition of the first meal has been shown to influence substrate oxidation for the
following 24 h [14], while skipping breakfast altogether is associated with greater risk of developing
T2D [15]. To date, no meal-size investigation has been performed in individuals with prediabetes,
who exhibit high peak glucose values in the morning irrespective of meal size [16,17]. Therefore, it
is important that the macronutrient composition of each meal investigated is consistent so that the
energy intake at each meal can be attributed to the observed outcomes.
To date, no study has determined the relative impact of energy intake or macronutrient composition
on daily glucose and insulin levels in adults with prediabetes. Furthermore, the impact of meal size
during prolonged periods of sitting in adults with prediabetes has not been examined. Accordingly,
the aim of the present investigation was to determine how manipulations to the distribution of energy
throughout the day, with meals of the same macronutrient composition, affect blood glucose and insulin
concentrations during prolonged sitting in men and women with overweight/obesity and prediabetes.
We hypothesised that a high-energy first meal would result in a less favorable postprandial glucose and
insulin profile throughout a day of prolonged sitting than a low-energy first meal.
2. Materials and Methods
2.1. Participants
Men and women (aged 40–70 years) with overweight/obesity (body mass index (BMI) ≥ 25
but <45 kg/m2), sedentary (i.e., watching at least 3 h television per day) and inactive (i.e., not
meeting physical activity guidelines of ≥150 min/week of moderate-intensity exercise for >3 months)
lifestyles, who presented with impaired fasting glucose (IFG; ≥6.0 mmol/L but <7.1 mmol/L) and/or
impaired glucose tolerance (IGT) after 2 h of a 75 g oral glucose tolerance test (OGTT; ≥7.8 mmol/L
but <11.0 mmol/L) [18] were recruited from local community advertisements. Exclusion criteria
were: diagnosis of T2D; pregnancy; current smoker; employment in a non-sedentary occupation;
previous bariatric surgery; and medications known to impact on measurements of blood glucose.
Following initial phone screening, potentially eligible participants attended laboratory screening,
which included written consent, fasting and 2 h OGTT blood sampling (n = 51). A separate subset of
individuals completed pre-laboratory HbA1c testing at a local pathology clinic (n = 10), where ≥6.0%
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(42 mmol/mol) HbA1c indicated potential eligibility and subsequently they attended confirmatory
laboratory OGTT testing (n = 1).
2.2. Study Design
This randomised crossover study was undertaken at the Australian Catholic University
(ACU) between February–September 2016 (Australian New Zealand Clinical Trial Registry number
ACTRN12615001216505) after approval from the ACU Human Research Ethics Committee (2015-209H).
Eligible participants attended the laboratory on seven separate occasions: Once for pre-trial body
composition (dual-energy X-ray absorptiometry (DXA) and resting energy expenditure measurement
(REE); and three visits per trial: (i) pre-trial glucose monitor insertion; (ii) trial day (07:30 to 18:15 h);
and (iii) post-trial visit (08:00 h next day). Two trial conditions were completed by each participant in a
randomised order, separated by at least 10-days washout (no monitoring of diet or physical activity).
Trial condition order was randomly assigned by a third party using computer-generated random
numbers and sealed opaque envelopes (block randomised, n = 4) and revealed to study personnel on
the day prior to the first trial.
2.3. Preliminary Measures
An initial screening visit confirmed prediabetes status by HbA1c testing and/or a 2 h OGTT (75 g
glucose solution (PoC Diagnostics, North Rocks, NSW, Australia), analysed on the YSI 2900 (YSI Life
Sciences, Yellow Springs, OH, USA)). Eligible participants attended pre-trial fasted measurements
of body composition (DXA; GE Lunar iDXA Pro, enCORE software Version 16) and REE using a
metabolic cart (TrueOneRMR, Parvo Medics, Sandy, UT, USA), calibrated for expired gas (15.99% O2,
1.00% CO2) and flow rate to determine resting energy expenditure (REE; kJ/d) from the average of the
final 20 of 45 min of data collected.
2.4. Study Protocol and Trial Conditions
Figure 1 shows the study protocol. Participants wore activity monitors (SenseWear Armband
(SWA), Bodymedia, Pittsburgh, PA, USA; activPAL3 tri-axial accelerometer, PAL-technologies Ltd.,
Glasgow, Scotland) for 48 h prior to and throughout each trial. Participants were asked to refrain from
moderate-vigorous physical activities (MVPA) for 48 h and caffeine and alcohol consumption for 24 h
prior to each experimental condition (verified using activity monitors and food diaries). Participants
on medications were instructed to take and record medications as usual on testing days.
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Figure 1. Study protocol: (A) overview of the entire study; (B) Overview of the trial days. Eligible 
participants (n = 13) with prediabetes completed two trial conditions in a randomised order separated Figure 1. Study pro ocol: (A) overview of the ntire study; (B) Overview of the trial days. Eligible
participants (n = 13) with prediabetes completed two trial conditions in a randomised order separated
by >10 days. Blood was collected hourly and 30 min post each meal. Meals were provided at 09:00,
13:00 and 17:00 h in different energy distribution relative to the condition (HE-BF: 20/30/50% EI;
LE-HF: 50/30/20% EI) with the same macronutrient composition in each meal (50% carbohydrate, 20%
protein and 30% fat).
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Participants attended the laboratory the day before each trial to have a continuous glucose monitor
(CGM; iPro2 with Enlite sensor; Medtronic, Northridge, CA, USA) inserted into the subcutaneous
tissue of their lower back, adhered with waterproof dressings; and were provided with a hand-held
glucometer (Accu-Chek Performa II, Roche Diagnostics Ltd., Rotkreuz, Switzerland) for CGM
calibration 1 h post insertion, pre-dinner and pre-sleep; and a standardised meal (33% daily EI;
50% CHO, 30% fat, 20% protein) to consume between 18:00 and 20:00 h. On the trial day, the CGM was
calibrated with finger stick measures pre-breakfast, -lunch, -dinner and -sleep, as well as fasting the
following morning.
On the morning of each experimental condition, participants arrived at the laboratory at ~07:30 h
and an indwelling cannula (22G; Terumo, Tokyo, Japan) was inserted into an antecubital forearm
vein of each participant. A blood sample (12 mL; EDTA) was taken and the cannula was regularly
flushed with saline. Participants were seated on a sofa chair by 08:00 h and instructed to remain seated,
with toilet breaks permitted when required (matched in the subsequent trial), throughout the trial
period until 18:00 h when the cannula was removed, and participants returned home. At ~07:45 h the
next morning, participants returned in a fasted state for a final blood sample and removal of monitors.
During each trial day, serial blood samples (12 mL, EDTA) were collected hourly and 30 min post
meals. Whole blood (1 mL) was transferred into a separate tube containing a DPP-IV inhibitor (Merck
Millipore, Darmstadt, Germany) additive for total glucagon-like peptide 1 (tGLP-1) stability, prior to
centrifugation. The EDTA and tGLP-1 tubes were centrifuged at 1800 g, 10 min at 4 ◦C. Plasma was
immediately aliquoted and stored at −80 ◦C for later analysis.
Trial conditions were based on a high-energy breakfast (HE-BF) with 50% EI at breakfast and
20% EI at dinner or a low-energy breakfast (LE-BF) with 20% EI at breakfast and 50% EI at dinner.
Both conditions had the same lunch (30% EI). Participants consumed meals within 20 min and water
ad libitum during the first trial condition (matched in the subsequent trial). After the evening meal,
participants were asked not to consume any other energy-containing foods or beverages (except water)
until they returned to the laboratory the following morning.
Meal Composition
Meals were provided to participants throughout each trial day with breakfast at 09:00 h, lunch at
13:00 h and dinner at 17:00 h. Total EI was individualised based on REE x 1.5 physical activity
factor. Each meal composition was 50% energy from CHO, 30% energy from fat and 20% energy from
protein. Foods selected for each meal (see Supplementary information, Table S1) were chosen to meet
the required composition and have a similar glycaemic index. Fibre content differed due to meal
size differences.
2.5. Biochemical Analysis
Plasma glucose concentration was measured using a hexokinase method at a commercial
laboratory (Melbourne Pathology, Collingwood, Victoria, Australia) with a CV < 1.9%.
Fasting triglycerides were analysed using a Cobas b 101 instrument (Roche Diagnostics Ltd., Basel,
Switzerland). Plasma insulin, connecting peptide (C-peptide) and tGLP-1 concentrations were
measured using a Luminex Analyzer (MAGPIX®; Human Metabolic Hormone Magnetic Bead Panel,
EMD Millipore, Burlington, MA, USA) following manufacturer’s instructions with intra-assay CV’s of
9.8%, 6.8% and 11.4%, respectively.
2.6. Data Analysis
Incremental area under the curve (iAUC) was used to assess the 4-h post-meal periods following
breakfast and lunch for venous plasma glucose for each condition (secondary outcome). The iAUC
was calculated using the trapezoidal rule to measure net AUC, with the initial measure prior to meal
commencement as baseline. Total AUC for plasma glucose, insulin, c-peptide, and tGLP-1 total from
08:00 to 17:00 h were calculated using the trapezoidal rule with a zero baseline. For CGM data, iAUC
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was calculated using the trapezoidal rule to measure the net AUC, with the 15 min period prior to
each meal commencement as baseline. Total AUC was calculated from CGM data from 08:00 to 18:00 h
to compare with venous measurements, as well as from 08:00 for 24 h total AUC. Mean 24 h glucose
concentration, the standard deviation (SDglucose) over 24 h, and measures of glycaemic variability
(mean amplitude of glycaemic excursions (MAGE) [19], continuous overall net glycaemic action for 1 h
(CONGA1) [20]) were analysed from CGM data using EasyGV [21]. Homeostatic model assessment
(HOMA of beta-cell function (HOMA2-%beta), insulin sensitivity (HOMA2-%S) and insulin resistance
(HOMA2-IR)) were calculated, using insulin concentrations [22].
Time spent sitting/lying, standing and stepping were estimated from activPAL3 data for the
waking periods (ascertained from self-reported sleep and waking times) of the habitual (pre-trial) days
and trial days using SAS 9.4 (SAS Institute, Cary, NC, USA), as described [8]. SWA generated estimates
of daily EE were measured through the recorded data based on the SWA proprietary algorithm,
as previously validated [23], using SenseWear Professional 7.0 software (Bodymedia Inc., Pittsburgh,
PA, USA).
2.6.1. Sample Size Calculations
Sample size calculations for the primary outcome of venous glucose concentrations were
based on mean daily glucose (from venous collections). Based on previous behavior and nutrition
interventions [10,24], it was estimated that a sample size of 22 would be needed to detect a repeated
measure between a treatment difference of 0.9 ± 1.04 mmol/L with a minimum power of 80% and
α = 0.05 (two-tailed test; G*Power 3.1.2 software). The sample size in the current study is less than our
original power calculations predicted to detect differences between treatments, but is similar to other
interventions that have investigated glycaemic responses in individuals with IGT [16,17,25]. The trial
ended prior to reaching our target sample size as a result of practical difficulties (each trial required
two full days in the laboratory) and the lower than expected potential participants with IFG/IGT
(21% of eligible participants). As a consequence, the study is likely to have been underpowered to
detect significant differences. Therefore, the following analyses should be considered exploratory.
2.6.2. Statistical Analysis
Statistical analyses were performed using SPSS (Version 22, SPSS Inc., Chicago, IL, USA).
Linear mixed models (LMM), using a scaled identity covariance structure, were used to analyse
baseline data and changes across time, using intervention allocation as the grouping variable and time
spent in MVPA (from SWA) in the 48 h pre-trial as a covariate. For the primary outcome of venous
glucose concentrations overtime, significance was set at p < 0.05 and post-hoc comparisons between the
groups were conducted when significant within the LMM based on the least significant squares (LSD)
test. While numerous analyses were conducted, no post-hoc corrections were made to account for
Type 1 error due to the exploratory nature of the analyses of secondary outcomes; therefore, only main
effects are reported. Residuals from the LMM were plotted to assess and confirm normally distributed




Of the 61 participants screened, 13 eligible participants (7 females, 6 males; mean ± SD, age:
60 ± 6 years; BMI: 33 ± 4 kg/m2; body mass (BM): 91.2 ± 11.9 kg; BF%: 43 ± 7%; fasting glucose:
5.6 ± 0.8 mmol/L; 2 h OGTT glucose: 8.9 ± 1.1 mmol/L) were randomised and completed both
conditions (Figure 2). Twelve participants were classified as having IGT, with one participant classified
as having IFG, with n = 8 taking medication (for hypertension (n = 4), hypercholesterolemia (n = 3),
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thyroid activity (n = 2) and depression (n = 2)). No differences were observed between conditions at
baseline, for anthropometric, biochemical, physical activity patterns or dietary intake (Table 1).
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Figure 2. Consolidated Standards of eporting Trials (CONSORT) flow diagram of participant
recruitment. For a full CONSORT statement see Supplementary File S1.
Table 1. Anthropometric, biochemical, physical activity and dietary information from participants with
prediabetes (n = 13) prior to each trial condition.
Condition
HE-BF LE-BF
Body mass (trial day; kg) a 91.6 ± 13.8 91.3 ± 13.8
Body composition b
Body mas (kg) 91.5 12.4
Fat mass (kg) 38.2 7.1
Lean mass (kg) 50.7 ± 10.4
Visceral adipose tissue (kg) 2.1 ± 0.7
Fasting concentrations c
Plasma glucose (mmol/L) 5.52 0.76 5.22 ± 0.63
Plasma insulin (mIU/mL) 23.6 13.4 21.7 ± 10.8
Plasma C-peptide (nmol/L) 0.69 ± 0.66 0.64 ± 0.49
Plasma tGLP-1 (pmol/L) 40.6 ± 9.6 39.7 ± 10.1
Triglycerides (mmol/L) 1.47 ± 0.51 1.69 ± 0.61
Total Cholesterol (mmol/L) 4.79 ± 1.42 5.06 ± 1.40
HDL cholesterol (mmol/L) 1.02 ± 0.28 1.03 ± 0.23
LDL cholesterol (mmol/L) 3.11 ± 1.27 3.24 ± 1.21
HOMA2-%beta 165 ± 80 183 ± 75
HOMA2-%S 41 ± 15 44 ± 19
HOMA2-IR 2.84 ± 1.21 2.74 ± 1.24
Physical activity time (min/day) d
Light-intensity 156 ± 52 149 ± 42
Moderate-intensity 49 ± 38 48 ± 24
Vigorous-intensity 0 ± 0 0 ± 0




Proportion of waking hours spent sedentary (%) e 65 ± 12 67 ± 12
Estimated daily energy expenditure (kJ/day) d 10,296 ± 2275 9772 ± 1461
Diet
Total energy intake (kJ/day) 7665 ± 2651 7519 ± 3128
Total carbohydrate (% of energy intake) 46.0 ± 7.0 46.0 ± 8.6
Total fat (% of energy intake) 31.6 ± 8.0 30.1 ± 5.6
Total protein (% of energy intake) 18.6 ± 5.3 19.3 ± 5.2
Resting energy expenditure (kJ/day) f 7311 ± 1221
Data are mean ± SD. Key: C-peptide, connecting peptide; tGLP-1, total glucagon like peptide 1; HE-BF, high-energy
breakfast condition; HOMA, homeostatic model assessment; IR, insulin resistance; LE-BF, low-energy breakfast
condition; %beta, steady state beta cell estimate; %S, insulin sensitivity. a Body mass was measured on scales while
fasted. b From DXA measures which were only measured at baseline on a single occasion for each participant.
c Fasting values are based on venous blood data from an average of two time points prior to the first meal. d From
SenseWear Armband accelerometer data. e From activPAL3 monitors during waking hours ≥ 10 h. f Only measured
at baseline as per DXA. No significant differences were observed between pre-condition measures (p > 0.05) using
students T-test.
3.2. Interventions
Participants consumed 11,528 ± 1882 kJ in each condition across a trial day. Habitual dietary
intake patterns were distributed similarly to the LE-BF condition, whereby participants consumed
19–21% EI at breakfast, 31–38% EI at lunch and 42–48% EI at dinner. Three-day food record analysis
revealed similar habitual daily macronutrient distributions to the trial meals (CHO (including fibre):
~48% EI; Fat: ~31% EI; Protein: ~19% EI).
Physical activity levels were low prior to both conditions, corresponding with low levels of
habitual EE in the 48 h pre-trial period (Table 1). On the day of trial, total daily EE and activity
patterns were similar between conditions (Table 2). The trial period differed to the habitual pre-trial
period whereby the daily EE was reduced (p < 0.001; Tables 1 and 2), the proportion of time standing
and moving was reduced and the proportion of time sitting increased (all p < 0.001), including the
accumulated amount of time spent sitting for >30 min blocks (p < 0.001; Table 2).
Table 2. Measures of activity calculated from activity monitors worn by individuals with prediabetes
(n = 13) in response to a high-energy first meal (HE-BF) or a low-energy first meal (LE-BF).
Measure Time HE-BF LE-BF Difference (95% CI)
Sitting (%) a Pre-trial 64 ± 11 65 ± 11 −1 (−6, 4)
Trial day 98 ± 2 * 98 ± 2 * 1 (−4, 6)
Post-trial 68 ± 10 71 ± 10 −2 (−6, 2)
Standing (%) a Pre-trial 27 ± 7 26 ± 8 1 (−3, 5)
Trial day 2 ± 1 * 2 ± 2 * 0 (−5, 4)
Post-trial 22 ± 8 20 ± 8 † 2 (−2, 6)
Stepping (%) a Pre-trial 9 ± 6 9 ± 4 0 (−2, 2)
Trial day 1 ± 1 * 1 ± 1 * −1 (−3, 1)
Post-trial 9 ± 5 9 ± 4 0 (−1, 2)
Sitting 30 min blocks (%) a Pre-trial 46 ± 15 50 ± 15 0 (−2, 2)
Trial day 96 ± 4 * 98 ± 3 * −1 (−3, 1)
Post-trial 57 ± 15 56 ± 23 0 (−2, 2)
Energy expenditure (kJ/day) b Trial day 9053 ± 1715 8561 ± 1370 613 (−243, 1469)
Data are mean ± SD; from LMM analyses, significantly different (p < 0.05) from * pre-trial and post-trial, † post-trial
only. a From Activpal activity monitors where, Pre-trial: includes 48 h of wear until 08:00 h on trial day; Trial: 08:00 h
to 18:00 h inclusive; Post-trial: 18:00 h to 08:00 h following day. b From SenseWear Armband monitors estimated
from total wear time (98%) over 24 h.
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3.3. Glycaemic Control
Mean plasma glucose from venous samples was higher in HE-BF (7.1 ± 1.1 mmol/L) compared to
the LE-BF condition (6.7 ± 0.8 mmol/L; +0.5 mmol/L, 95% CI: 0.1–0.9 mmol/L; p = 0.014; Figure 3A).
Accordingly, plasma glucose AUCtotal was greater in the HE-BF (71.5 ± 12.0 mmol/h/L) compared to
the LE-BF condition (66.8 ± 7.8 mmol/h/L; +5.7 mmol/h/L, 95% CI: 1.2–10.1 mmol/h/L; p = 0.019).
The postprandial glycaemic response, measured by iAUC in the 4 h post-breakfast period was 44 ± 59%
greater in the HE-BF condition compared to LE-BF (+2.9 mmol/h/L, 95% CI: 0.4–5.4 mmol/h/L;
p = 0.03; Figure 3B). There were no differences between conditions in peak glucose post-breakfast
(HE-BF: 9.0 ± 1.9 mmol/L; LE-BF: 8.6 ± 1.4 mmol/L; +0.4 mmol/L, 95% CI: −0.3–1.1 mmol/L).
However, in the 4 h post-lunch meal period a 55 ± 36% greater iAUC was observed in the LE-BF
condition (+4.8 mmol/h/L, 95% CI: 2.6–7.0 mmol/h/L; p = 0.02; Figure 3B), due to a decrease in
plasma glucose below baseline levels in the LE-BF condition prior to the lunch meal (Figure 3A).
Interstitial CGM results were similar to venous glucose for total AUC8-6 (i.e., a comparative
time measurement, Table 3), and for the iAUCs for the post-breakfast (HE-BF: +105 ± 133% greater;
+2.9 mmol/h/L, 95% CI: 1.0–5.0 mmol/h/L; p = 0.007) and -lunch (LE-BF: +109 ± 33% greater;
+5.3 mmol/h/L, 95% CI: 3.4–7.1 mmol/h/L; p < 0.001;) periods (Figure 3D). The 4 h post-dinner iAUC
was similar between conditions (+1.5 mmol/h/L, 95% CI: −0.2–3.2 mmol/h/L; p = 0.08; Figure 3D).
Despite differences in CGM iAUC, total AUC and mean glucose from CGM over 24 h were not different
between conditions (Figure 3C and Table 3).
A similar pattern for glucose response to meals was observed in both venous and CGM glucose
measures (Figure 3A,C). Plasma glucose concentrations were higher from 30 min to 2 h post-breakfast
in the HE-BF condition but decreased below baseline just before lunch in the LE-BF condition.
No differences between conditions were observed the morning following each trial for venous glucose
concentrations (Figure 3A) or in CGM iAUC overnight (21:00–08:00 h) (Figure 3D). Despite differences
in CGM iAUC for the first two meal periods, overall measures of glycaemic variability were not
different between conditions (SD, MAGE and CONGA1; Table 3).
Table 3. Measures of glycaemia calculated from a continuous blood glucose monitor (CGM).
Measurements from individuals with prediabetes (n = 13) in response to a high-energy breakfast
(HE-BF) or a low-energy breakfast (LE-BF).
Measure HE-BF LE-BF Difference (95% CI) p-Value
AUCtotal (mmol/h/L) 155.4 ± 15.8 153.5 ± 16.8 1.91 (−7.22, 11.03) 0.66
AUCtotal8-6 (mmol/h/L) 69.8 ± 8.4 65.3 ± 7.4 4.43 (0.64, 8.21) 0.026
Mean glucose (mmol/L) 6.53 ± 0.65 6.45 ± 0.70 0.08 (−0.30, 0.46) 0.66
SDglucose (mmol/L) 0.99 ± 0.34 1.00 ± 0.43 −0.02 (−0.27, 0.24) 0.89
MAGE (mmol/L) 2.48 ± 1.24 2.63 ± 1.27 −0.15 (−1.0, 0.70) 0.71
CONGA-1 6.05 ± 0.62 5.80 ± 0.63 0.25 (0.63, −0.13) 0.17
Data are mean ± SD, analysed using LMM; AUC, area under the curve; AUCtotal8-6, total AUC between 08:00 and
18:00 h for CGM glucose; CONGA-1, continuous overlapping net glycaemic action at 1 h; iAUC, incremental area
under the curve; MAGE, mean amplitude glucose excursions; SD, standard deviation.
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13:00 and 17:00 h on both condition days. Vertical lines represent the 4 h iAUC analysis periods. Data are mean ± SD. From LMM analyses, significantly different
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3.4. Insulin, C-Peptide and tGLP-1
A main effect of time was observed as plasma insulin concentrations increased from 30 min
post-breakfast in both conditions (p < 0.001) to a larger magnitude in the HE-BF condition
(time × group: p < 0.001; Figure 4A). Insulin was higher in the HE-BF than the LE-BF condition
until 2 h post-lunch (p < 0.03) and was elevated above baseline from 1 h post meal for the entire day
(p < 0.001). Insulin concentrations in the LE-BF condition returned to concentrations similar to baseline
at pre-lunch (13:00 h, p = 0.39), but were elevated above baseline for all other time points (p < 0.04).
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Figure 4. Plas centrations of Insulin (A), C-peptide (B), and tGLP-1 (C), from
participants with prediabetes (n = 13) throughout (08:00–18: 0 h) trial conditions (high-energy breakfast
(HE-BF; black bars and symbols) and low-energy breakfast (LE-BF; white bars and symbols)) and
the orning after (08:00 h); and the associate total AUC (08:00–17:00 h) for insulin (D), C-peptide
(E) and tGLP-1 (F). Data are mean ± SD. From LMM analyses, * significantly different (p < 0.01)
between conditions.
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C-peptide and tGLP-1 concentrations were elevated above baseline from 30 min post-breakfast
until 18:00 h (both main effect, time: p < 0.001; Figure 4B,C). From 2 h post-breakfast to 30 min post-lunch,
C-peptide concentrations were lower in LE-BF compared to HE-BF (p < 0.03). Greater concentrations
of tGLP-1 were observed 1 h post-breakfast to pre-lunch in the HE-BF condition (main effect: group:
p < 0.001). Consequentially, total AUC for insulin, C-peptide and tGLP-1 measured between 08:00 and
17:00 h was greater in the HE-BF compared to the LE-BF condition (p < 0.01, Figure 4D–F). No differences
were observed between conditions in fasting insulin, C-peptide, or tGLP-1 concentrations the morning
following each trial.
4. Discussion
This is the first study to investigate acute postprandial responses to a high- versus low-energy
first meal of the same macronutrient composition during a day of prolonged uninterrupted
sitting in individuals with prediabetes. The study design is novel since energy intake at each
meal was experimentally manipulated but importantly, and in contrast to previous investigations,
the macronutrient composition of each meal was matched. We observed that the first feeding occasion
was the “priming meal” for subsequent glucose responses, independent of energy content, but by
early afternoon perturbations in glucose and insulin were similar in response to both feeding patterns.
No differences were observed in mean 24 h glucose or AUC from CGM analyses, but differences in
blood glucose patterns throughout the morning and following lunch were evident.
Over the long term glycaemic control, and in particular glycaemic variability (i.e., peaks and
nadirs), is clinically relevant in the development of complications (such as impaired endothelial
function and damage due to oxidative stress) associated with type 2 diabetes [26,27]. In our cohort
of individuals with prediabetes, glycaemic variability measures did not differ between conditions.
Furthermore, we found similar peak venous plasma glucose concentration after the first meal despite
the vastly different energy content (50% vs. 20% of total EI). Hence, the observed benefits to glycaemic
control from a large first meal that has previously been demonstrated are most likely due to the
disparity in meal composition (i.e., CHO content) of the meals [10,12]. In the context of Western
breakfast meal composition as used in the current intervention, the effects of skewing energy intake
towards a large first meal did not acutely improve daily glycaemic control. Whether chronic adoption
of a large-CHO-based first meal [12] improves daily glycaemic control for individuals with prediabetes
requires further investigation. Previous investigations have fed a greater proportion of daily CHO
intake into the first meal [10,12], rather than a more even distribution of energy across lunch and
evening meals, to show improved glycaemic control. Accordingly, the macronutrient composition of
the meal in conjunction with the energy content is an essential consideration when manipulating meal
size and timing to improve postprandial and daily rhythms of glucose in individuals with prediabetes.
In the current investigation, the relatively small iAUC glucose response post-dinner meal in
both conditions, compared to breakfast, highlights the importance of the first meal for control of
daily hyperglycaemia in individuals with prediabetes. These findings support previous reports of
exaggerated peak blood glucose responses in individuals with prediabetes after the first meal when
meal size, independent of composition, is the same [17] or smaller [16]. Despite the high-energy first
meal eliciting the largest perturbations in postprandial blood glucose concentrations, such differences
did not persist throughout the 24 h monitoring period. Consequently, to counteract the large and
prolonged rise in blood glucose observed in the high-energy compared to the low-energy first meal
condition, an exaggerated morning insulin response was observed.
Elevated insulin concentrations have been observed in individuals with T2D following
consumption of a large breakfast [12], but not in response to a chronic large breakfast meal pattern in
women with overweight or obesity [10]. The return to baseline in plasma insulin concentrations before
lunch in the low-energy first meal condition suggests the smaller first meal allows insulin-resistant
individuals to process the glucose load without excess insulin secretion, thereby lowering the total
AUC insulin. Given the hyperinsulinemic and hyperglycaemic consequences of a high-energy first
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meal observed in individuals with prediabetes, it could be speculated that such an energy distribution
pattern in the long term may lead to the development of defective beta-cells, reducing insulin secretion
and impairing glucose tolerance [28].
Plasma C-peptide concentrations tracked the insulin responses and provided an indirect measure
of the insulin-secretory activity of the beta-cells [29]. C-peptide concentrations did not return to baseline
levels throughout either condition, most likely due to the slow clearance from the circulation [30].
Total GLP-1 was elevated 1 h post-first meal in both conditions but to a greater extent with a high-energy
first meal condition. The tGLP-1 responses to both conditions showed a lack of oscillations between
meals that have been observed in healthy individuals [30]. Unlike insulin and C-peptide, differences
in tGLP-1 were only observed between conditions until the second meal and the elevation of tGLP-1 in
both conditions after the second meal supports the second meal phenomenon of incretin hormones
playing an important role in attempting to reduce postprandial hyperglycaemic responses [12].
While the mechanisms underlying the second meal phenomenon are unclear, for individuals with T2D
the second meal is potentiated by the insulin secretion in response to the first meal [31], as presently
observed for responses to both large and small first-meals in individuals with prediabetes.
We chose to investigate individuals with prediabetes since the transition from prediabetes to
T2D has been shown to be delayed or prevented through lifestyle interventions [32–34]. Furthermore,
the circadian responses of glucose and insulin of healthy, normal weight participants, where glucose
tolerance and insulin sensitivity are reduced in the evening [13,35], are different to those in individuals
with T2D [36]. The use of CGM allowed for the measurement of total AUC glucose across a 24 h
period, rather than simply adding the post meal AUCs. It also provides insights into the changes
in interstitial glucose between meals and lack of change in interstitial blood glucose throughout the
night. While there were small or no differences between the conditions in these measures, there were
inter-individual differences within the cohort highlighting the variable nature of IGT/IFG.
We maintained strict control of activity levels throughout the day of the experimental intervention
to replicate the modern environment where obesity and T2D diagnosis are often synonymous with
decreased physical activity. As the post-first meal period is important for daily glucose control for
individuals with prediabetes [16,17], incorporation of specific post-breakfast physical activity could be
a prudent approach to optimise postprandial hyperglycaemic responses to any first meal, regardless
of size. Indeed, there is growing evidence supporting activity after mealtimes reducing postprandial
glucose and 24 h glucose concentrations in individuals with T2D [25,37,38].
A limitation of the present study is the lack of venous sampling after 1800 h and consequently
the inability to characterise the postprandial insulin, C-peptide or GLP-1 responses after the dinner
meal. Furthermore, the timing of meals was similar to a time-restricted feeding protocol [39] which
may have exacerbated the postprandial hyperglycaemic response to the lunch and dinner meals.
While the randomised within-subjects study design a powerful we acknowledge that the sample
size was smaller than originally intended. Despite multiple secondary outcome analyses, we did not
correct for multiple comparisons given the exploratory nature of the analyses and the importance of
identifying variables of interest for further study. Consequently, there is a risk of a Type 1 error and
therefore results should be interpreted with caution. These considerations highlight the need for a
larger, longer-term intervention, where meal size is the modifiable factor and each meal composition is
controlled. However, food availability/choices at mealtimes often dictate the composition so there is
also a need to investigate meal size with the consideration of typical meal compositions (i.e., higher
carbohydrate intakes at breakfast and higher protein at dinner).
5. Conclusions
Our results support a role for first meal energy intake to influence postprandial glucose and
insulin responses in adults with prediabetes, independent of macronutrient composition. In contrast
to the results of studies of meal energy distribution, the clinical advantage of a high-energy first
meal to improve daily blood glucose regulation was not evident in this investigation in individuals
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with prediabetes. We conclude that for adults with prediabetes who experience prolonged sedentary
periods, particularly in the hours leading to lunch, a low-energy first meal may be desirable for
postprandial glucose and insulin regulation, although 24 h glycaemic control was not impaired or
improved by a high-energy first meal of the same composition.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/6/733/s1,
Table S1: Meal composition and nutritional values for a 10900 kJ (~2600 kcal) example diet for each condition,
File S1: CONSORT checklist.
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